Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

The Gilead Sciences logo is seen on the company website. (Photo: Ivan Radic/Flickr/cc)

'Big Win': Caving to Pressure Campaign, Gilead Sciences Relinquishes Monopoly Claim for Promising Coronavirus Treatment

"There's no doubt that the prospect of an enormous public backlash is what made the difference."

Government watchdog Public Citizen celebrated Wednesday afternoon as pharmaceutical giant Gilead Sciences backed off a monopoly claim for its drug that may treat the coronavirus which has sickened more than 487,000 people worldwide. Gilead, Public Citizen said, must now commit to ensuring the drug is accessible to all who need it.

Public Citizen applauded the news as a "big win" for those who spoke out against Gilead Sciences, whose former lobbyist, Joe Grogan, now serves on President Donald Trump's so-called "coronavirus task force."

"It was outrageous that Gilead ever sought an 'orphan drug' designation for remdesivir, which aims to treat a patient population that easily may number in the tens of millions in the U.S. alone," Peter Maybarduk, director of Public Citizen's Access to Medicines program, said in a statement. "Thankfully, under pressure, the company has backed down. There's no doubt that the prospect of an enormous public backlash is what made the difference."

Gilead's claim to "orphan" drug status for remdesivir, one of several drugs being tested to treat the coronavirus, officially known as COVID-19, drew outrage this week from Public Citizen, Sen. Bernie Sanders (I-Vt.), and dozens of other public interest advocates. 

Trump's Food and Drug Administration granted the orphan status—which would allow a seven-year monopoly on the drug and could keep it out of reach of many Americans by preventing other companies from developing generic versions—even though Gilead developed remdesivir with at least $79 million in government funds. Orphan status is generally reserved for companies that may not recoup their research costs and for drugs which treat conditions affecting fewer than 200,000 people.

"Gilead must have been feeling the heat," James Love, director of public interest non-profit Knowledge Ecology International, told NPR after Gilead reliquished its claim. "I think it's embarrassing to take something that's potentially the most widespread disease in the history of the pharmaceutical industry and claim it's a rare disease."

Soon after Public Citizen was joined by 50 other groups in demanding Gilead end its "unconscionable abuse of a program designed to incentivize research and development of treatments for rare diseases," the company announced on Wednesday it would proceed without orphan drug status. 

Public Citizen said that Gilead Sciences must go further than simply withdrawing its claim of orphan drug status, and actively work to ensure that remdesivir is widely produced and available for all who need it.

"Gilead must do more than make vague promises of reasonable pricing," Maybarduk said. "It should commit right now to license the right and needed know-how to manufacture remdesivir to all qualified producers, in exchange for a modest royalty."

"If the drug proves viable as a COVID-19 treatment," he added, "the U.S. and the world will need the product available at a low price that reflects both the public health need and the potentially enormous market—with production at an unprecedented scale." 


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
We need your help.

Support progressive journalism.

Common Dreams is not your average news site. We don't survive on clicks or advertising dollars. We rely entirely on your support. And without it, our independent progressive journalism simply wouldn’t exist. Every gift of every amount matters.

Join the fight and support our common dreams today.

'Sorely Disappointed' by Court Ruling, Pipeline Foes Demand Biden 'Act Immediately to Stop Line 3'

"Every day President Biden refuses to stop the Line 3 pipeline is a slap in the face to environmental justice communities and a renewed breaking of his promises on climate and Indigenous rights."

Brett Wilkins, staff writer ·


300+ Progressive Groups Urge Corporations to Ditch ALEC for Pushing Voter Suppression Bills

"If corporations really believe in protecting our democracy and the right to vote, they must end their affiliation with ALEC," said one advocate.

Kenny Stancil, staff writer ·


Reality Winner's Release From Federal Prison Met With Calls for Full Pardon for the NSA Whistleblower

Winner will serve the rest of her five-year sentence under the supervision of a halfway house.

Julia Conley, staff writer ·


Analysis Highlights Biden Proposal to End $84 Billion Gift to Big Oil Buried in Trump Tax Scam

"We can stop this insane corporate welfare and use it to pay for a renewable energy future."

Andrea Germanos, staff writer ·


Intent on Appeasing Manchin, US Blocks G7 Progress on Phasing Out Coal

"Once again Joe Manchin is casting a heavy shadow."

Julia Conley, staff writer ·